Preoperative Chemoradiotherapy for Oesophageal Cancer: a Systematic Review and Meta-analysis

Overview

Journal Gut

Specialty Gastroenterology

Date 2004 Jun 15

PMID 15194636

Citations 160

Authors

F Fiorica

D Di Bona

F Schepis

A Licata

L Shahied

A Venturi

A M Falchi

A Craxi

C Camma

Affiliations

Soon will be listed here.

Abstract

Background: The benefit of neoadjuvant chemoradiotherapy in oesophageal cancer has been extensively studied but data on survival are still equivocal.

Objective: To assess the effectiveness of chemoradiotherapy followed by surgery in the reduction of mortality in patients with resectable oesophageal cancer.

Methods: Computerised bibliographic searches of MEDLINE and CANCERLIT (1970-2002) were supplemented with hand searches of reference lists.

Study Selection: Studies were included if they were randomised controlled trials (RCTs) comparing preoperative chemoradiotherapy plus surgery with surgery alone, and if they included patients with resectable histologically proven oesophageal cancer without metastatic disease. Six eligible RCTs were identified and included in the meta-analysis.

Data Extraction: Data on study populations, interventions, and outcomes were extracted from each RCT according to the intention to treat method by three independent observers and combined using the DerSimonian and Laird method.

Results: Chemoradiotherapy plus surgery compared with surgery alone significantly reduced the three year mortality rate (odds ratio (OR) 0.53 (95% confidence interval (CI) 0.31-0.93); p = 0.03) (number needed to treat = 10). Pathological examination showed that preoperative chemoradiotherapy downstaged the tumour (that is, less advanced stage at pathological examination at the time of surgery) compared with surgery alone (OR 0.43 (95% CI 0.26-0.72); p = 0.001). The risk for postoperative mortality was higher in the chemoradiotherapy plus surgery group (OR 2.10 (95% CI 1.18-3.73); p = 0.01).

Conclusions: In patients with resectable oesophageal cancer, chemoradiotherapy plus surgery significantly reduces three year mortality compared with surgery alone. However, postoperative mortality was significantly increased by neoadjuvant chemoradiotherapy. Further large scale multicentre RCTs may prove useful to substantiate the benefit on overall survival.

Citing Articles

Evolving Therapeutic Strategies in Esophageal Squamous Cell Carcinoma: Advances and Perspectives.

Liu Z, Kim M J Cancer Prev. 2025; 29(4):99-104.

PMID: 39790226 PMC: 11706721. DOI: 10.15430/JCP.24.026.

Survival benefit of adjuvant therapy following neoadjuvant therapy in patients with resected esophageal cancer: A retrospective cohort study.

Jia W, Li C, Liu C, Hu R PLoS One. 2024; 19(11):e0304937.

PMID: 39561158 PMC: 11575812. DOI: 10.1371/journal.pone.0304937.

Updated German guideline on diagnosis and treatment of squamous cell carcinoma and adenocarcinoma of the esophagus.

Porschen R, Fischbach W, Gockel I, Hollerbach S, Holscher A, Jansen P United European Gastroenterol J. 2024; 12(3):399-411.

PMID: 38284661 PMC: 11017771. DOI: 10.1002/ueg2.12523.

Esophageal cancer - the utility of PET/CT in staging prior to chemoradiation.

Deja A, Wlodarczyk M Rep Pract Oncol Radiother. 2024; 28(5):608-611.

PMID: 38179288 PMC: 10764044. DOI: 10.5603/rpor.96869.

Identification of Optimal Parameters for Assessing Lymph Node Status of Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.

Huang X, Jiang D, Jian Z, Zeng Z, Zhang S, Fan H Ann Surg Oncol. 2023; 31(2):883-891.

PMID: 38038788 DOI: 10.1245/s10434-023-14135-6.

References

Walsh T, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy T . A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996; 335(7):462-7. DOI: 10.1056/NEJM199608153350702. View

Bosset J, GIGNOUX M, Triboulet J, Tiret E, Mantion G, Elias D . Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997; 337(3):161-7. DOI: 10.1056/NEJM199707173370304. View

Nygaard K, Hagen S, Hansen H, Hatlevoll R, Hultborn R, Jakobsen A . Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg. 1992; 16(6):1104-9; discussion 1110. DOI: 10.1007/BF02067069. View

Le Prise E, Etienne P, Meunier B, Maddern G, Ben Hassel M, Gedouin D . A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994; 73(7):1779-84. DOI: 10.1002/1097-0142(19940401)73:7<1779::aid-cncr2820730702>3.0.co;2-t. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Apinop C, Puttisak P, Preecha N . A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 1994; 41(4):391-3. View

Juni P, Witschi A, Bloch R, Egger M . The hazards of scoring the quality of clinical trials for meta-analysis. JAMA. 1999; 282(11):1054-60. DOI: 10.1001/jama.282.11.1054. View

Jaeschke R, Oxman A, Guyatt G . To what extent do congestive heart failure patients in sinus rhythm benefit from digoxin therapy? A systematic overview and meta-analysis. Am J Med. 1990; 88(3):279-86. DOI: 10.1016/0002-9343(90)90154-6. View

Hulscher J, van Sandick J, de Boer A, Wijnhoven B, Tijssen J, Fockens P . Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002; 347(21):1662-9. DOI: 10.1056/NEJMoa022343. View

10.

Wayman J, Forman D, Griffin S . Monitoring the changing pattern of esophago-gastric cancer: data from a UK regional cancer registry. Cancer Causes Control. 2002; 12(10):943-9. DOI: 10.1023/a:1013756531219. View

11.

Nicolucci A, Grilli R, Alexanian A, Apolone G, Torri V, Liberati A . Quality, evolution, and clinical implications of randomized, controlled trials on the treatment of lung cancer. A lost opportunity for meta-analysis. JAMA. 1989; 262(15):2101-7. View

12.

Moher D, Cook D, Eastwood S, Olkin I, Rennie D, Stroup D . Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999; 354(9193):1896-900. DOI: 10.1016/s0140-6736(99)04149-5. View

13.

Urba S, Orringer M, Turrisi A, Iannettoni M, Forastiere A, Strawderman M . Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001; 19(2):305-13. DOI: 10.1200/JCO.2001.19.2.305. View

14.

. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002; 359(9319):1727-33. DOI: 10.1016/S0140-6736(02)08651-8. View

15.

Muller J, Erasmi H, Stelzner M, Zieren U, Pichlmaier H . Surgical therapy of oesophageal carcinoma. Br J Surg. 1990; 77(8):845-57. DOI: 10.1002/bjs.1800770804. View

16.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

17.

Barendsen G . Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys. 1982; 8(11):1981-97. DOI: 10.1016/0360-3016(82)90459-x. View

18.

Daly J, Karnell L, Menck H . National Cancer Data Base report on esophageal carcinoma. Cancer. 1996; 78(8):1820-8. DOI: 10.1002/(sici)1097-0142(19961015)78:8<1820::aid-cncr25>3.0.co;2-z. View

19.

Kelsen D, Bains M, Burt M . Neoadjuvant chemotherapy and surgery of cancer of the esophagus. Semin Surg Oncol. 1990; 6(5):268-73. DOI: 10.1002/ssu.2980060508. View

20.

Faivre J, Forman D, Esteve J, Gatta G . Survival of patients with oesophageal and gastric cancers in Europe. EUROCARE Working Group. Eur J Cancer. 1999; 34(14 Spec No):2167-75. DOI: 10.1016/s0959-8049(98)00329-3. View